Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ Hopes Coupling GLP-1 Bydureon and SGLT-2 Forxiga Is Paradigm Shift

Executive Summary

AstraZeneca hopes positive results from its DURATION-8 trial combining its GLP-1 drug Bydureon and SGLT2 product Forxiga for the first time will spur use – and sales – for each, and open the way for an additional line of defense for type 2 diabetes patients before they are moved onto insulin.

You may also be interested in...



Semaglutide Should Transform Novo Nordisk's Prospects, CSO Says

Novo Nordisk's investigational GLP-1 agonist semaglutide promises to elevate the Danish group's product offering and market position, its CSO says in an interview with Scrip.

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel